Skip to main content

Biogemma Licenses Evogene's Corn Genes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biogemma has licensed rights to genes from Evogene that it will use to develop corn hybrids with improved yield and drought tolerance, Evogene said today.

The corn lines Paris-based Biogemma will develop under the worldwide, exclusive agreement include genes that the companies evaluated under a collaboration agreement that was started in 2006. Biogemma and Evogene validated corn lines incorporating these genes through field trials in the US and in Israel over the past two years.

"Improved plant yield and drought tolerance are perhaps the most critical needs in today's worldwide agriculture, and as such are key targets for Evogene's ag-bio trait program," Ofer Haviv, Evogene's president and CEO, said in a statement.

Rehovot, Israel-based Evogene's core platform uses computational technologies for gene discovery and high-throughput systems for gene validation.

Financial terms of the agreement were not released.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.